factors such as recent surgery or major trauma, the risk of recurrence at 1 year is 1% and patients can safely discontinue anticoagulants. 5 However, more than half of patients have unprovoked VTE events and the risk for recurrent VTE is substantial, reaching 10% in the first year after stopping anticoagulants, 5% in the following year, 6 and 30% at 8 years. 7 The associated case-fatality rate of recurrent VTE is 3.6%. 8 The International Society on Thrombosis and Haemostasis (ISTH)
suggests continuing anticoagulation in those whose risk of recurrent VTE 1 year after stopping treatment is >5% 9 and oral anticoagulants effectively reduce the risk of recurrent VTE by 80% to 90%. 10 The 2016 American College of Chest Physicians (ACCP) guidelines suggest extended oral anticoagulation in patients with unprovoked VTE and low-moderate bleeding risk. 4 It is important to note that the ACCP guidelines make a stronger recommendation to avoid prolonged anticoagulants in high bleeding risk patients, defined as an annual major bleeding risk of >6%. 4 Patients deemed to be high bleeding risk are those with at least two of several risk factors such as age >65, prior bleeding, (metastatic) cancer, liver or renal failure, thrombocytopenia, prior stroke, diabetes, and anemia. This categorization strata has not been validated, but is based on available evidence on the risks of anticoagulation-associated bleeding. 4 With continuing anticoagulation comes the potential harm of major bleeding which is fatal in around 11% of cases. 8 In recent years, the relative safety of DOACs over VKAs has led to a consideration for extended, rather than limited, duration anticoagulation therapies for VTE.
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The next important question to consider is which anticoagulant to choose to balance the benefit of preventing recurrent VTE and minimize the harms of bleeding? This review article summarizes the evidence available for extended antithrombotic treatment of VTE and introduces the COVET trial, a direct comparison of VKAs to rivaroxaban and apixaban, for extended treatment of unprovoked VTE.
| ORAL ANTICOAGULANTS
Vitamin-K antagonists (VKAs) were the only class of oral anticoagulants for many decades, and were therefore the standard of care for extended treatment of VTE. In the last decade, direct oral anticoagulants (DOACs) have been studied and approved for use in the secondary prevention of recurrent VTE. These include the direct thrombin inhibitor dabigatran and direct Factor Xa inhibitors rivaroxaban and apixaban. Acetylsalicylic acid (ASA) is the only antiplatelet agent to be evaluated in secondary prevention of VTE.
Randomized controlled trials (RCTs) have compared combinations of ASA, full dose and reduced dose DOACs, standard and low-intensity VKAs, and placebo for prevention of recurrent VTE. 
| VKAs

| Dabigatran
Dabigatran is the only DOAC to be compared to VKA for extended treatment of VTE. In the RE-MEDY trial, 19 patients deemed to be high risk for recurrent VTE were randomized to dabigatran 150 mg BID vs VKA target INR 2-3. Rates of recurrent VTE were similar between the dabigatran and VKA groups. Safety outcomes such as major bleeding (MB) and MB or clinically relevant non-major bleeding (CRNMB) were twice as low in the dabigatran group as in the VKA group (Table 2) . Although dabigatran was similarly effective and had few bleeding events compared to VKA, acute coronary syndrome was more common in the dabigatran group than VKA group (0.9% and 0.2%, respectively; P = .02).
Simultaneous to RE-MEDY was the RE-SONATE trial, a placebo-controlled comparison to dabigatran for extended treatment of VTE. 19 Not surprisingly, anticoagulation with dabigatran 150 mg BID significantly reduced the rate of recurrence compared to placebo by >90%. Although MB events were similar between the groups, MB/CRNMB events were significantly higher in the anticoagulant arm (Table 2 ). There were no differences in acute coronary syndrome with one event occurring in each group.
| Rivaroxaban
The EINSTEIN-EXT Study was the first to compare a DOAC (rivaroxaban) to placebo for extended VTE therapy. 20 Standard dose rivaroxaban 20 mg daily was compared to placebo for a median duration of 265 days. As in the RE-SONATE trial, anticoagulation was superior to placebo for reducing the primary efficacy outcome of recurrent VTE events, with one recurrent event being a fatal PE in the placebo group.
MB was the primary safety outcome which occurred only in patients on rivaroxaban and all events were non-fatal. MB/CRNMB events were significantly higher in the rivaroxaban group than placebo (Table 2) .
To determine whether a reduced dose of rivaroxaban 10 mg daily is as effective at lowering risk of recurrent VTE as rivaroxaban 20 mg daily, the EINSTEIN Investigators conducted the EINSTEIN CHOICE trial randomizing patients to rivaroxaban 20 mg daily, 10 mg daily, or ASA 100 mg daily. 21 Unlike the EINSTEIN-EXT study, only a minority of patients in EINSTEIN CHOICE had index VTE that was definitely unprovoked (75% vs 40%, respectively) ( Table 1 ). The primary efficacy outcome, symptomatic recurrent VTE (fatal or non-fatal PE, and DVT), was significantly lower in both rivaroxaban groups (Table 2) . MB was the principal safety outcome and rates were similar between all groups ( Table 2 ). The composite of MB/CRNMB rates were also similar and not statistically significantly different (Table 2) 
| Apixaban
| Aspirin
Two trials have evaluated the efficacy of ASA 100 mg daily for secondary prevention of recurrent VTE. The WARFASA 23 and ASPIRE 24 trials were both placebo-controlled trials in patients with unprovoked index VTE who had completed anticoagulation treatment. The primary efficacy outcome was symptomatic recurrent VTE (fatal or non-fatal PE, and DVT) and MB the safety outcome in WARFASA, while ASPIRE used MB/CRNMB composite. In WARFASA the rate of recurrent VTE in the ASA group was nearly half that in the placebo group (Table 2) and MB rates were the same in both groups.
The ASPIRE trial 24 was unable to meet its original sample size due to slow recruitment and was reduced, with plans to pool final results with those of WARFASA trial. ASPIRE alone was unable to show a statistically significant benefit to ASA compared to placebo for recurrent VTE reduction. The rate of MB/CRNMB events was similar between groups ( 
| Edoxaban
Edoxaban is the third direct Factor Xa inhibitor and the last agent approved for treatment of VTE. Like dabigatran, the acute treatment of VTE requires a 5-day lead in with heparins prior to starting the oral agent. 25 Edoxaban has not been evaluated for extended therapy for secondary prevention of VTE. A review of clinicaltrials.gov shows no such pending trials for this DOAC. Patient comorbidities must also be considered when prescribing extended anticoagulation. 29 Patients using medications that are ASA, acetylsalicylic acid; BID, bis in die, twice daily; CI, confidence interval; CRNMB, clinically relevant non-major bleeding; DOAC, direct oral anticoagulant; HR, hazard ratio; INR, international normalized ratio; MB, major bleeding; VKA, vitamin-K antagonist; VTE, venous thromboembolism. a Primary outcome was recurrent VTE and fatal PE except for RE-SONATE (recurrent VTE or unexplained death) and AMPLIFY-EXT (recurrent VTE and death from any cause). 
| CONSIDERATIONS FOR CHOOSING ANTICOAGULANTS
| LIMITATIONS OF DOAC TRIALS FOR EXTENDED VTE TREATMENT
There are several limitations to these trials that do not permit ease of data transfer to clinical practice when determining which patients are high risk and may benefit from secondary prevention. These include heterogeneous patient populations of both provoked and unprovoked index thromboses, selection bias, variable treatment durations, and most importantly, lack of direct comparisons between DOACs. Indirect comparisons via network meta-analysis show that dabigatran, rivaroxban, and apixaban reduce risk of recurrent VTE by more than 80% and are associated with mild-moderate bleeding risk. 10 These gaps in evidence highlight the decisional dilemmas faced by patients, clinicians, and policy makers.
We recently initiated a clinical trial that is a head-to-head com- is clinically relevant bleeding events and the primary efficacy outcome is recurrent VTE. We anticipate this trial will demonstrate that rivaroxaban and apixaban are safer than and as effective as warfarin.
In summary, while awaiting the results of the head-to-head COVET trial for extended treatment of unprovoked VTE, it is essential to remember that anticoagulants are more effective than aspirin, and compared to no treatment, apixaban and rivaroxaban will substantially reduce the risk of recurrent VTE. Future studies, including the COVET trial, will determine whether simplicity and safety of DOACs make them the strongly preferred choice for extended VTE management. Follow up assessments
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